The bankruptcy underscores the great risks of investing in many of the companies that have gone public via mergers with special-purpose acquisition corporations.

Bankrupt genetic test company 23andMe may face opposition from the U.S. government if it tries to sell itself to a foreign ...

Following biotechnology company 23andMe's filing for bankruptcy, losing its CEO, and trying to find a buyer last month, the ...

Me on Sunday filed for bankruptcy in the U.S. after struggling with weak demand for its ancestry testing kits and a 2023 data ...

Leaders of the House Committee on Energy and Commerce said they are investigating how 23andMe’s bankruptcy might affect ...

The company's bankruptcy has spotlighted the vulnerability of private consumer genetic testing data.

Genetic analysis company 23andMe (ME) announced this week it's declaring bankruptcy and pursuing a sale, leading many customers to pursue deleting their data from the company. 23andMe was founded ...

Just before the 23andMe SPAC deal closed ... giving investors the impression it is a risk-free investment. Some companies do not find appropriate acquisition targets and have to redeem the ...

23andMe bankruptcy underscores the risk of investing in most SPACs. - MarketWatch photo illustration/iStockphoto 23andMe is going bankrupt — underscoring the great ...

Just before the 23andMe SPAC deal closed ... giving investors the impression it is a risk-free investment. Some companies do not find appropriate acquisition targets and have to redeem the ...